Product Pipeline

This therapy employs‌¶ a mixture of immune cells from pati₽ ®ents with hepatocellular∑♠  carcinoma, including γδT cells, NK ceσπ₩lls, and iNKT cells. γδT cells demon¥δ♦strate powerful and multifaceted'®‍ anti-tumor characteri™✔×stics; they not only directly ±β kill tumor cells but also exe<'rt antibody-dependent c↕₹✔ ellular cytotoxicity (ADCC) against th♣φ♣®em. NK cells can rapidly initiate$∞₽ cytotoxic responses without♠♦ the need for recognizing tumor↕≈γ-specific antigens. iNKT ©←cells integrate essential features of≈‍∑ both NK and T cells, functioning as a & Ω€"bridge" between innate an‍★€φd adaptive immunity a¶εnd playing a signific''ant role in anti-tumor immune r&✘™esponses. The synergistic effects of th↔¥♣×ese cell types significantly enh♦$→ance their cytotoxic capabil×←ities. Moreover, these cells expr'ε¶★ess markers such as CD6♠φπ≈9, CD49a, CD103, CXCR6, and ♥£CXCR3, which provide them with liver-h'✘oming and liver-resident capa¥€÷bilities, allowing effective accum'σ≥ulation in the liver to tar∞≠±αget liver cancer cells. These aβ ctivated killer immune cells expresγ≤§♣s high levels of NKG2D m&♠olecules, which can recognize NKG™∑2DL, a receptor highly∞δ$× expressed on liver cancer ce§₩lls, thereby enhancing their ♠♠ε‍cytotoxic efficiency.